Difference between revisions of "Category:Anti-SLAMF7 antibodies"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) |
||
| Line 1: | Line 1: | ||
| − | Drugs that have some demonstrated degree of efficacy through the inhibition of Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7). Elotuzumab is the first FDA-approved medication in this category. | + | Drugs that have some demonstrated degree of efficacy through the inhibition of Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7), also commonly called CS1. [[Elotuzumab (Empliciti)|Elotuzumab]] is the first FDA-approved medication in this category. |
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
Revision as of 02:05, 24 July 2017
Drugs that have some demonstrated degree of efficacy through the inhibition of Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7), also commonly called CS1. Elotuzumab is the first FDA-approved medication in this category.
Pages in category "Anti-SLAMF7 antibodies"
This category contains only the following page.